GSK spin­out NeRRe splits the pipeline, cre­ates its own spin­out

Five years af­ter NeRRe Ther­a­peu­tics spun out of GSK with some of its un­want­ed work in neu­ro­sciences, the UK biotech is ex­e­cut­ing a spin­out of its own.

NeRRe has tak­en a neu­rokinin-1,3 re­cep­tor an­tag­o­nist — with po­ten­tial as a hor­mone re­place­ment ther­a­py — and hived it off in­to a new biotech called KaNDy Ther­a­peu­tics. Now KaNDy will take it in­to a Phase IIb study for post­menopausal va­so­mo­tor symp­toms.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.